Abstract: By a genome-wide gene analysis of expression profiles of over 50,000 known or putative gene sequences in peripheral blood, the present inventors have identified a consensus set of gene expression-based molecular biomarkers associated with subclinical acute rejection (subAR). These genes sets are useful for diagnosis, prognosis, monitoring of subAR.

Abstract: The invention includes compositions including magnesium-lithium alloys containing various alloying elements for medical implant devices. The devices are constructed of the compositions or have applied thereto a coating formed therefrom. Within the structure of the magnesium-lithium alloy, there is a co-existence of alpha and beta phases. The invention also includes methods of preparing the magnesium-lithium alloys and articles, such as medical implant devices, for use in medical applications, including orthopedic, dental, craniofacial and cardiovascular surgery.

Abstract: The present invention provides engineered penicillin G acylase (PGA) enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, and methods of using the engineered PGA enzymes.

Abstract: The present invention relates to compositions and methods for the in vitro diagnosis of prostate cancer, wherein said compositions comprise an antibody binding to progastrin and said methods comprise the use of an antibody binding to progastrin.

Abstract: Provided herein are methods for developing selected reaction monitoring mass spectrometry (LC-SRM-MS) assays.

Abstract: Disclosed herein is a particle containing an inner liposomal vesicle (ILV) encapsulating a therapeutic agent; an outer liposomal vesicle (OLV) encapsulating the ILV; a membrane fusion-promoting agent; and a pH-altering agent. Also disclosed are methods of delivering a therapeutic agent to a subject comprising: a) providing a herein disclosed particle b) triggering ILV and OLV fusion; and c) releasing the therapeutic agent outside of the OLV. Also disclosed are methods for treating a disease in a subject in need thereof comprising: administering to a subject a herein disclosed particle. Also disclosed are methods to release insulin to an environment comprising increased glucose levels, the method comprising exposing to the environment a herein disclosed particle.

Abstract: Provided herein are host cells or host cellular expression systems that express a membrane protein. Also, methods are provided that use such host cells or host cellular expression systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the functional characterization of membrane proteins, as well as for screening and drug discovery efforts targeting membrane proteins.

Abstract: The present invention provides engineered transglutamirase enzymes, polynucleotides encoding the enzymes, compositions comprising the enzymes, methods of producing these enzymes, and methods of using the engineered transglutaminase enzymes.

Abstract: An interdigitated electrode biosensor includes an insulating layer configured to fully cover a sensor forming region of a substrate, a first interdigitated microelectrode configured such that a plurality of first protruding electrodes is arranged in a shape of a comb on the substrate, a second interdigitated microelectrode configured such that a plurality of second protruding electrodes is arranged in a shape of a comb and each interdigitates with the plurality of first protruding electrodes, and a plurality of receptors that is immobilized in a space between the first interdigitated microelectrode and the second interdigitated microelectrode and reacts specifically to target biomaterials.

Abstract: According to one aspect, the present disclosure provides a method of identifying a substrate of a transglutaminase using a peptide array comprising a plurality of peptides. The method includes the steps of contacting the peptides in the peptide array with the transglutaminase, allowing the transglutaminase to bind to the peptides, and identifying the substrate of the transglutaminase.

Abstract: The present invention relates to an antibody-fluorescent dye conjugate capable of cancer cell-specific fluorescence imaging diagnosis. The fluorescent dye comprises a covalently labeled antibody and is quenched by interaction with an amino acid residue such as tryptophan, tyrosine, histidine, and methionine in the antibody and upon binding of the antibody to an antigen present on a cell surface to emit fluorescence, whereby cells having a target antigen thereon can be imaged for diagnosis. When using the antibody-fluorescent dye conjugate according to the present invention during in vitro cell assays, high-throughput screening of cells, and cytodiagnosis based on microfluidics, the presence of cancer cells having a specific antigen expressed thereon can be detected at high specificity and sensitivity without a washing process, and the position of primary and metastatic cancer cells can be detected at high contrast within a short time.

Abstract: Provided herein are sulfo n-hydroxysuccimidyl ester (sulfo-SE) linked peptides, methods of synthesis thereof, and methods of using such peptides for labeling of biomolecules. In particular, peptides comprising non-alkyl group such as serine, threonine, cysteine, tyrosine, glutamic acid, and aspartic acid are stably modified (e.g., without autoreactivity) with a sulfo-SE group and used to label or otherwise modify biomolecules.

Abstract: Disclosed herein are antibodies having binding specificity to the amino acid sequences Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) and Thr Val Glu Val Asp (SEQ ID NO:14), and methods of detecting cell death in a sample, comprising contacting the sample with a first antibody specific for a C-terminal amino acid sequence Ala Ser Ser Gly Leu Thr Val Glu Val Asp (SEQ ID NO:1) or Thr Val Glu Val Asp (SEQ ID NO:14) of a CK18 protein fragment having a C-terminal amino acid sequence of Val Glu Val Asp (SEQ ID NO:2) and a second antibody that specifically binds an epitope that is present in both full-length CK18 and the CK18 protein fragment, and that does not overlap with SEQ ID NO:1 or SEQ ID NO:14, under conditions such that the CK18 protein fragment present in the sample specifically binds to the first antibody and the second antibody, wherein one of the antibodies is bound to a solid support and the other antibody is bound to a detection moiety capable of producing a signal; optionally removing any unbo

Abstract: Among the various aspects of the present disclosure is the provision of a method of detection, treatment, and monitoring of cardiovascular disease or a foot wound by detection of a novel biomarker, Fatty Acid Synthase (FAS). Briefly, therefore, the present disclosure is directed to methods that allow for improved, noninvasive, and reliable diagnosis of these conditions, particularly in subjects suffering from Type 2 Diabetes (T2D).

Abstract: The invention relates to ex-situ biosensors that impedimetrically detect cardiac biomarkers of interest in a bodily fluid sample derived from a patient. The biosensors include a multi-array of vertically aligned platinum wires having immobilized thereon an aptamer that is selected to specifically and selectively bind to the cardiac markers of interest. The biosensors are contacted with a portion of the bodily fluid sample, and the aptamer binds to the cardiac markers of interest in the bodily fluid sample. As a result, an electrochemical impedance signal is generated and therefore, a change in electrochemical impedance is indicative of the presence of the cardiac markers of interest in the bodily fluid sample. The biosensors are point-of-care, on-demand devices that can be used in a medical environment, as well as in domestic settings.

Abstract: A monitoring method based on the detection of human ingested substances, comprises: acquiring the mass spectrum in the terminal of each matrix assisted laser ionization analysis time-of-flight mass spectrometer, and storing each mass spectrum and its corresponding identity information, sampling time and residence information when sampling in the database; obtaining the mass spectrum characteristic ion peaks of known substances and/or unknown substances in each mass spectrum; and counting the frequency of the mass spectrum characteristic ion peak of the known substance and/or the unknown substance, and early warning of the mass spectrum characteristic ion peak whose frequency is greater than the first threshold.

Abstract: The present invention pertains to novel analgesics useful for treating mechanical pain. The invention suggests the use of inhibitors of ?-tubulin acetylation for inhibition of neurological sensations that are mediated by sensory neurons. The perception of mechanical pain is can be modulated by altering the ?-tubulin acetylation, in context of the invention in particular by modulation of the expression and/or activity of the enzyme ?-tubulin acetyltransferase (Atat). The invention provides the medical application of ?-tubulin acetyltransferase inhibitors as analgesics and a screening method for the identification of compounds useful in the treatment of pain.

Abstract: The present disclosure provides methods to quantify tau phosphorylation at specific amino acid residues to predict time to onset of mild cognitive impairment due to Alzheimer's disease, stage Alzheimer's disease, guide treatment decisions, select subjects for clinical trials, and evaluate the clinical efficacy of certain therapeutic interventions.

Abstract: A method for producing a target directivity function that includes a set of spatially biased HRTFs. A set of left ear and right ear head related transfer functions (HRTFs) are selected. The left ear and right ear head HRTFs are multiplied with an on-camera emphasis function (OCE), to produce the spatially biased HRTFs. The OCE may be designed to shape the sound profile of the HRTFs to provide emphasis in a desired location or direction that is a function of the specific orientation of the device as it is being used to make a video recording. Other aspects are also described and claimed.

Abstract: Disclosed herein is a method of producing collagen particles. Each of the collagen particle is characterized in having a particle size of about 10-250 ?m, in which the integrity of collagen fibers therein is relatively intact.

Abstract: The present invention relates to detecting cleavage activity of an enzyme. The various aspects of the invention include an enzyme detection device, kit, method and use for detecting or measuring the presence in a test sample of the activity of an enzyme capable of cleaving a substrate. The invention also relates to indicator and binding molecules useful for carrying out the invention. The enzyme substrate contains a hidden binding site which is only revealed upon cleavage by the enzyme.

Abstract: Disclosed is a means of enabling the construction of a more accurate PIVKA-II immunoassay system using monoclonal antibodies against human prothrombin. The PIVKA-II assay method according to the present invention comprises measuring PIVKA-II in a sample by an immunoassay using an anti-PIVKA-II antibody or an antigen-binding fragment thereof which specifically binds to PIVKA-II and a mixture of a first anti-prothrombin antibody or an antigen-binding fragment thereof which recognizes hydrophilic PIVKA-II molecules and a second anti-prothrombin antibody or an antigen-binding fragment thereof which recognizes hydrophobic PIVKA-II molecules.

Abstract: The instant invention relates to a qualitative predictive method, to a method, use and kit applied to the early differential diagnosis of the most prevalent forms of bacterial and viral meningitis, enabling to detect and distinguish the different forms of meningitis. The invention uses a qualitative predictive method based on combined detection and sequential analysis of the presence/absence of at least three out of four specific biomarkers.

Abstract: A method and cartridge for determining an amount of at least two analytes in a biological sample and an automatic analyzer are disclosed. The cartridge may comprise a cartridge inlet, a sample holding chamber fluidically connected to the inlet, and two or more metering chambers. Each metering chamber may comprise a sample inlet, a sample outlet, and a metered outlet for dispensing a predetermined volume. At least one sample distribution channel is connected between the sample outlet of a metering chamber with a sample inlet of another metering chamber. For each metering chamber, a connecting tube fluidically connects the sample inlet with the sample holding chamber, a microfluidic structure for processing the sample into a processed sample connects to the sample outlet, and a measurement structure fluidically connects to the microfluidic structure and enables measurement of the processed sample to determine the amount of the analyte in the processed sample.

Abstract: The present inventors discovered that additional aggregation of low-pI antibody can be suppressed by removing formed antibody aggregates after a certain period of time following Protein A column purification, acidic treatment, and neutralization. Furthermore, the present inventors found that efficient impurities removal for a low-pI antibody can be accomplished by using an anion exchange resin in the Bind/Elute mode and then a hydrophobic interaction chromatography or multimodal chromatography resin, compared with conventional methods.

Abstract: An arrangement for the individualized in-vitro patient blood analysis includes a holography module, a Raman spectroscopy module, a biomarker module and a flow controller which are connected in a data and information transmitting manner to a central control and computer unit, which has an information transmitting connection to a database, wherein the modules are fluidically connected to a common blood sample supply and supplies for fluid other than blood via the flow controller.

Abstract: Disclosed are methods to induce dislodgement of target prostatic cells from the prostate organ, collecting said cells, and subsequently examining the cell population. Such methods comprise the administration of an agent that facilitates the dislodgement of the target cells from within the prostate, which then migrate into the urethra. Exemplary agents include 5 alpha-reductase inhibitors. The cells induced to pass into the urethra are then collected non-invasively, such as through urine or semen samples. Such collection is further strategically calculated relative the administration of the agent so as to maximize the sample collection of the target cells of interest.

Abstract: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogs, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising [antigenic molecule of first source]-[analyte auto antibody]-[antigenic molecule of second source]. The antigenic molecule of first source is immobilized to a solid phase, the second is labelled.

Abstract: A method of screening a sample of body fluid obtained from an animal subject for analyte autoantibodies reactive with one or more antigenic molecules selected from pancreatic islet cell antigenic molecules (GAD, 1A2) and insulin, or one or more variants, analogs, derivatives or fragments thereof, and a kit for use in such a method. After addition of the sample one or more complexes comprising [antigenic molecule of first source]-[analyte auto antibody]-[antigenic molecule of second source]. The antigenic molecule of first source is immobilized to a solid phase, the second is labeled.

Abstract: Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (PEDV) or porcine delta coronavirus (PDCoV). Also disclosed are embodiments of a composition comprising the coronavirus proteins and antigens, and embodiments of a method of using such a composition. Applications for the composition include, but are not limited to, use in the preparation of antibodies against the proteins and antigens, use as reference markers for coronavirus proteins, and/or use in an immunogenic composition, such as in a vaccine composition.

Abstract: The present invention is in the field of coagulation diagnostics and relates to methods for detecting modulators of GPIb-thrombin interaction in a sample. To this end, the sample is contacted with isolated mutated GPIb? protein and thrombin, and the formation of a complex between mutated GPIb? protein and thrombin is determined.

Abstract: A method of digesting a lignocellulosic material is disclosed. In one embodiment, the method comprises the step of exposing the material to an effective amount of Streptomyces sp. ActE secretome such that at least partial lignocellulosic digestion occurs.

Abstract: Biosensors, compositions comprising biosensors, methods of producing biosensors, and methods of using biosensors are disclosed. The biosensors comprise a fluorogen-activating peptide and a blocking peptide. The fluorogen-activating peptide and blocking peptide are covalently linked through a peptide linker. The blocking peptide associates with the fluorogen-activating peptide thereby blocking an active domain of the fluorogen-activating peptide when the linker is in an unmodified state. The peptide linker may contain an amino acid sequence that is specifically recognized as a modification substrate by a cognate enzyme. The fluorogen-activating peptide and the blocking peptide at least partially disassociate when the linker is modified by an enzyme, thereby allowing the fluorogen-activating peptide to bind a cognate fluorogen and modulate a fluorescence signal.

Abstract: The present invention describes the method for determining the risk of future major adverse cardiovascular events, which comprises detection proteolytic fragments of IGFBP-4 or IGFBP-5 (insulin-like growth factor binding protein 4 or insulin-like growth factor binding protein 5) in patients' blood. The present invention provides antibodies and immunoas-says, suitable for specific measurement of proteolytic fragments of IGFBPs. In current invention the IGFBP fragments are suggested to be utilized as blood biomarkers for the risk prediction of major adverse cardiovascular events (MACE).

Abstract: Methods of neutralizing circulating antibody and mitigating the risk of clinically significant adverse responses to incompatible transfusions and transplantations are described. The methods comprise the administration to the subject of dispersible antigen-lipid constructs.

Abstract: Methods and kits for reducing non-specific binding in an immunoassay for PIVKA-II in a test sample are described, in which the test sample is reacted with an anti-prothrombin antibody in the presence of one or more of the following additives: skim milk, saponin, CaCl2, MgCl2, and a sulfobetaine zwitterionic detergent.

Abstract: The present invention relates to the identification of certain biomarkers for use in identifying patients who have, or are likely to develop an IL-33 mediated disease or disorder and who are more likely to respond to therapy with an IL-33 antagonist. The invention also relates to methods of treatment of an IL-33-mediated disease or disorder in a patient by administering an IL-33 antagonist to the patient in need thereof and monitoring the effectiveness of therapy using the biomarkers described herein. Also provided are methods for decreasing the level of at least one biomarker in a subject suffering from an IL-33-mediated disease or disorder, and methods for treating such diseases or disorders according to the expression levels of one or more biomarkers. The methods of the present invention comprise administering to a subject in need thereof a pharmaceutical composition comprising an interleukin-33 antagonist.

Abstract: Disclosed are sensitive methods for detecting a target substance in low concentrations. The method can include immobilizing a target substance to a solid phase; incubating the immobilized target substance with a reporter enzyme detection probe in solution under conditions for forming target: enzyme detection probe complexes; washing the solid phase to remove any unbound reporter enzyme detection probe; incubating the target: enzyme detection probe complex with a reporter enzyme detection probe substrate in substrate reaction solution to generate one or more ionizable products; and detecting one or more of the one or more ionizable products using mass spectrometry (MS).

Abstract: Devices, systems, methods, and kits are provided for performing separation, immobilization, blotting, and/or detection of analytes from biological samples. In some embodiments, the devices are constructed from two solid substrates with surfaces in contact. The devices include a plurality of channels formed from indentations in these surfaces. The indentations can be aligned with each other across the interface between the substrates, and realigned by shifting or sliding one substrate relative to the other. In some embodiments, the devices are constructed from three layers of a solid substrate. A separation channel in the middle layer of the device is first used for analyte separation. The middle layer can then be slid relative the top and/or bottom layer, thereby aligning the separation channel with a blotting membrane. Analytes can then be transferred to the membrane using electrodes in the top and bottom layers.

Abstract: An object of the present invention is to provide a method of measuring the amount of a compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin, which method is suitable for reduction of noise originating from impurities and determination of the exact amount of a target compound. The present invention provides a method of measuring the amount of a target compound containing a sugar chain in a biological sample by a sandwich immunoassay method using a labeled lectin (including cases where a target compound-capturing substance other than an antibody is used as a ligand), the method containing adding a sugar chain compound which competes (crosses) with impurities contained in the biological sample in binding with the labeled lectin.

Abstract: Fluidic systems and methods for analysis are provided. In some embodiments, systems and methods for improved measurement of absorbance/transmission through fluidic systems are described. Specifically, in one set of embodiments, optical elements are fabricated on one side of a transparent fluidic device opposite a series of fluidic channels. The optical elements may guide incident light passing through the device such that most of the light is dispersed away from specific areas of the device, such as intervening portions between the fluidic channels. By decreasing the amount of light incident upon these intervening portions, the amount of noise in the detection signal can be decreased when using certain optical detection systems.

Abstract: Provided is an ultrasonic probe that is capable of easily dissipating heat generated therein using porous carbon allotrope foams. The ultrasonic probe includes: a matching layer; a piezoelectric layer disposed on a bottom surface of the matching layer; and a backing layer disposed on a bottom surface of the piezoelectric layer and formed of porous carbon allotrope foams and backing materials.

Abstract: A biosensor molecule comprises: a protease amino acid sequence; at least one sensor comprising at least one sensor amino acid sequence which is responsive to at least one target molecule; and an inhibitor of the protease activity of said protease amino acid sequence; wherein the biosensor is switchable from a protease active to a protease inactive state, or from a protease inactive to a protease active state when said sensor responds to said target molecule. The biosensor protease may be a protease of a virus such as a Potyvirus or a Flavivirus wherein the inhibitor is an autoinhibitory peptide derived from the virus. The biosensor may respond to the target molecule allosterically or may be cleaved by a target protease molecule.

Abstract: The present invention relates to a method for measuring Troponin I in a sample comprising the steps of providing a sample, contacting the sample with a monoclonal anti-Troponin I antibody coupled to a magnetic label, contacting the sample with a polyclonal anti-Troponin I antibody coupled to a sensor surface and detecting the magnetic label on the sensor surface. The invention further relates to a device and a cartridge for measuring Troponin I in a sample.

Abstract: The present invention provides a composition comprising a fluorescent nucleic acid probe that can be cleaved by enzymatic and non-enzymatic means, and methods of using the same. Advantageously, the nucleic acid probe may be used to detect and quantify nucleic acid cleavage in vitro, in situ, ex vivo, and in vivo.

Abstract: Compositions and methods for determining post-transfusion survival or toxicity of red blood cells and the suitability of red blood cell units for transfusion by measuring the levels of one or more markers in a red blood cell sample are provided.

Abstract: The present invention is related to a method for detection of a biological target in an affinity assay, the method comprising the steps of providing a biological sample volume containing the biological target, adding a first capturing moiety to the biological sample volume comprising the biological target, wherein the first capturing moiety is adhered to a particle, concentration of the captured biological target into an elution volume that is smaller than the biological sample volume in step a), cleavage of the first capturing moiety or the biological target from the particle and direct or indirect detection and/or quantification of the biological target in a sandwich or competitive affinity assay format, wherein the biological target is associated with at least one capturing moiety, preferably at least two capturing moieties.

Abstract: Methods for diagnosing rheumatoid arthritis (RA) are disclosed, using measurement of the CCL8 protein level in a test sample from a subject. Testing for CCL8 as an indicator of RA can be combined with testing for other indicators of RA, including clinical assessments, imaging or other RA markers such as Rheumatoid factor (RF). CCL8 testing can be used for discriminating RA from other diseases or conditions, evaluating the severity of RA. Related diagnostic reagents, kits, pharmaceutical compositions, and methods for identifying a candidate substance as a therapeutic agent for treating rheumatoid arthritis are also described.

Abstract: A polypeptide represented by SEQ ID NO: 1 and a method for treatment of a tumor and another disease associated with abnormal cell proliferation are described. The method includes administering a pharmaceutically-effective amount of the polypeptide to a patient in need thereof.

Abstract: The present invention provides a single domain specific binding molecule having the structure FW1-CDR1-FW2-HV2-FW3a-HV4-FW3b-CDR3-FW4 in which the Framework Regions FW1, FW2, FW3a, FW3b, and FW4, the Complementarity Determining Regions CDR1 and CDR3, and the Hypervariable Regions HV2, and HV4 have amino acid sequences as defined which provide a high affinity anti-human serum albumin (HSA) binding domain.